DELTICOM/MYTYRES.CO.UK
29.3.2018 11:32:03 CEST | Business Wire | Press release
Easter is just around the corner, and it’s time for motorists to start thinking about changing to summer tyres. If you are switching to last year’s summer tyres, you need to check them for quality, otherwise the risk of serious accidents increases. Do the tyres have cracks or bumps? Is the tread depth acceptable? If you see signs of damage or irregularities, and of course if the tread depth is less than the recommended three millimetres, you should invest in new summer tyres. When selecting tyres, you will be spoilt for choice. Mytyres.co.uk explains what to look for, and what information you need to find the right tyres for you.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180329005427/en/
Tyre size
Each vehicle is limited to certain tyre dimensions. You need to know what they are before buying tyres, as the wrong size tyres increases the risk of accidents. Information about the correct size can be found on the vehicle registration certificate, as well as on the sidewall of the tyres currently on your vehicle.
Speed index
The speed index indicates the permissible maximum speed of a tyre. Manufacturers only guarantee long-term problem-free use up to this limit. The speed index must be in accordance with the car’s maximum speed. It can be found on the vehicle registration certificate, as well as on the sidewall of the tyre. In the case of summer tyres, the specified value may be exceeded, unlike winter tyres. The speed index limit must never be exceeded in winter tyres.
Driving behaviour
The driver’s individual style and the main use of the tyres are also important factors in the purchase decision. If you are a sporty driver or often go on long journeys, you may need a different tyre than drivers who are more concerned with cost-effectiveness or comfort, or who only travel short distances.
“The tyres are the only part of the vehicle that touch the road, making them crucial for safety, fuel consumption and comfort. That’s why it’s crucial to think about checking and changing them in plenty of time – and not to focus solely on the price when buying new ones”, says Thierry Delesalle from Mytyres.co.uk . The online shop offers a wide range of summer and all-season tyres for every vehicle and every need. The central input field allows you to search for tyres by type, model, and size, or alternatively you can enter your particular vehicle model. The product descriptions also contain all the information and explanations you need about the tyre’s properties and performance. Also, drivers can find customer reviews and official tyre test results from the online tyre testing platform, Tyretest.com , giving customers an extra helping hand to find the right tyres quickly and easily. If you don’t fancy getting your toolbox out after buying new tyres, you can also have them sent to one of over 2,000 fitting partners, where specialists will fit them to your car for you free of charge.
You can find all the information you need on changing to summer tyres in this video from Mytyres.co.uk : https://www.youtube.com/watch?v=OE5wWgUmi2k .
About Mytyres.co.uk
There are over 100 tyre brands and more than 25,000 models of tyres to be found at Mytyres.co.uk - also including the latest best-rated tyres from official comparison tests. The product portfolio not only includes tyres for cars , motorbikes , lorries, commercial vehicles and buses , but also wheel-tyre sets , rims and car replacement parts and accessories . Particularly practical: new tyres can be delivered quickly and free of charge* to any address provided. When purchasing tyres, buyers can also choose from more than 2,000 professional car workshop partners across the UK and have the tyres sent to them directly for professional fitting. Many of our partner workshops also offer additional services, such as tyre storage.
*2 tyres and more
Buy tyres online:
www.mytyres.co.uk , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch , www.123pneus.ch , www.autobandenmarkt.nl , www.123pneus.fr , www.gommadiretto.it , www.neumaticos-online.es and in many other Delticom online shops
Tyre tests: www.tyretest.com
All about tyres from A to Z: www.tyres.net
Information about the company: www.delti.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180329005427/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom